Smith & Nephew SNATS, Inc. $SNN Shares Sold by Inspire Advisors LLC

Inspire Advisors LLC lowered its position in Smith & Nephew SNATS, Inc. (NYSE:SNN) by 11.1% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 18,351 shares of the medical equipment provider’s stock after selling 2,287 shares during the quarter. Inspire Advisors LLC’s holdings in Smith & Nephew SNATS were worth $562,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Richards Merrill & Peterson Inc. lifted its stake in Smith & Nephew SNATS by 500.0% during the first quarter. Richards Merrill & Peterson Inc. now owns 1,200 shares of the medical equipment provider’s stock worth $34,000 after purchasing an additional 1,000 shares during the last quarter. Banque Transatlantique SA purchased a new position in Smith & Nephew SNATS in the first quarter valued at approximately $52,000. Bessemer Group Inc. raised its holdings in Smith & Nephew SNATS by 111.9% during the second quarter. Bessemer Group Inc. now owns 3,709 shares of the medical equipment provider’s stock worth $114,000 after purchasing an additional 1,959 shares in the last quarter. Geneos Wealth Management Inc. lifted its position in shares of Smith & Nephew SNATS by 15.0% during the 1st quarter. Geneos Wealth Management Inc. now owns 4,149 shares of the medical equipment provider’s stock worth $118,000 after buying an additional 541 shares during the last quarter. Finally, Brooklyn Investment Group lifted its position in shares of Smith & Nephew SNATS by 3,086.3% during the 1st quarter. Brooklyn Investment Group now owns 4,429 shares of the medical equipment provider’s stock worth $126,000 after buying an additional 4,290 shares during the last quarter. Institutional investors and hedge funds own 25.64% of the company’s stock.

Wall Street Analyst Weigh In

SNN has been the subject of a number of research analyst reports. Royal Bank Of Canada reissued an “outperform” rating on shares of Smith & Nephew SNATS in a research report on Monday, October 20th. Sanford C. Bernstein set a $37.50 price target on shares of Smith & Nephew SNATS and gave the stock a “market perform” rating in a research note on Tuesday, October 14th. Wall Street Zen downgraded shares of Smith & Nephew SNATS from a “strong-buy” rating to a “buy” rating in a research report on Friday, October 3rd. Kepler Capital Markets raised shares of Smith & Nephew SNATS to a “strong-buy” rating in a report on Monday. Finally, Weiss Ratings reiterated a “hold (c+)” rating on shares of Smith & Nephew SNATS in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $35.75.

Smith & Nephew SNATS Price Performance

NYSE:SNN opened at $32.28 on Thursday. The company has a current ratio of 3.00, a quick ratio of 1.40 and a debt-to-equity ratio of 0.60. The firm’s fifty day moving average price is $35.68 and its 200 day moving average price is $33.15. Smith & Nephew SNATS, Inc. has a 1-year low of $23.69 and a 1-year high of $38.79.

Smith & Nephew SNATS Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.